P rimary intracardiac tumors, such as myxomas, occur in at least 7 of 10 000 individuals 1 and are an important clinical problem whose pathogenesis is poorly understood. Cardiac myxomas may occur as isolated findings or as components of heritable multisystem disease. Several inherited syndromes that relate lentiginosis to myxomas have been reported, 2, 3 and the most commonly associated myxomas are intracardiac, particularly atrial. Multiple acronyms have been proposed for such lentiginosis: atrial myxoma syndromes, including LAMB (Lentigines, Atrial myxomas, Mucocutaneous myxomas, and Blue nevi) syndrome and NAME (Nevi, Atrial myxoma, Myxoid neurofibroma, and Ephelides) syndrome. However, recent nosology 3, 4 aggregates them under the broader category of Carney complex.
In the autosomal dominant syndrome Carney complex, 3-8 affected individuals variably express the disease phenotype but typically exhibit cutaneous disease (lentigines, ephelides, and blue nevi) in the setting of intracardiac myxomas. Cutaneous hyperpigmentation most commonly occurs on the face and trunk as well as on the lips, sclera, and mucosal surfaces of oral and genital regions and is present in Ն95% of individuals affected by Carney complex. 5 Lentiginosis is present at birth, intensifies during puberty, and may fade with aging during adulthood. Associated intracardiac myxomas are often atrial, but ventricular tumors also occur. Familial syndromic atrial myxomas are estimated 1 to account for 7% of all atrial myxomas and may be particularly refractory to therapy. Whereas sporadic atrial myxomas occur most commonly as isolated left atrial lesions in middle-aged women, familial atrial myxomas 6 occur in individuals of all ages without sex preference and are often bilateral and/or multicentric. Although sporadic atrial myxomas are usually highly amenable to curative surgical resection, familial lesions frequently recur, often at locations distant from the initial site of surgery. 6, 8 Extracardiac myxomas 4 -6 occasionally occur in Carney complex. Such extracardiac myxomas are usually mucocutaneous, but less often, myxomas of the breast, testis, adrenal gland, thyroid gland, and brain are seen. Nonmyxomatous tumors such as pituitary adenoma, breast fibroadenoma, and psammomatous melanotic schwannoma are also observed. Cutaneous and neoplastic disease in the Carney complex may be associated with nonneoplastic endocrine abnormalities, most commonly Cushing syndrome secondary to primary pigmented nodular adrenocortical hyperplasia. Pituitary and thyroid dysfunction have also been noted. A variety of hematological, immunological, and rheumatic disorders (eg, anemia, polycythemia, fever, rheumatoid arthritis, vasculitis, systemic lupus erythematosus, and Raynaud's phenomenon) have all been associated with atrial myxomas. Such systemic abnormalities have been suggested 9 -11 to be secondary to myxoma secretion of the cytokine interleukin 6 and frequently resolve with tumor resection. Histopathological studies of Carney complex lentigines and cardiac myxomas have not demonstrated features unique to this syndrome to differentiate them from their sporadic counterparts.
The gene defect that produces cardiovascular and cutaneous disease in Carney complex remains unknown, and no cytogenetic abnormalities have consistently been associated with the Carney complex. Because of the known proto-oncogene functions of GTP binding proteins, DeMarco et al 12 hypothesized that defects in G s␣ might explain Carney complex, but they were unable to identify any such mutations. Telomeric rearrangements in sporadic atrial myxomas have occasionally been noted [13] [14] [15] to involve chromosomes 2, 12, and 17. Stratakis et al 7 used linkage analysis to propose a chromosomal locus in a 6.4-cM interval on chromosome 2p, but we have recently proved that Carney complex is genetically heterogeneous. 16 In this study, we now show that a genetic defect on chromosome 17q causes Carney complex in at least 4 unrelated families.
Methods

Clinical Status
Informed consent was obtained from all participants in accordance with approval by the respective review boards of participating institutions. All family members were evaluated by a thorough history and physical examination without knowledge of genotype status. If there was any evidence of dermatologic, cardiac, or endocrine disease suggestive of Carney complex, patients were further evaluated by electrocardiography, transthoracic echocardiography, serum chemistry, and hematology.
Genotype Analyses
Peripheral blood was obtained from each family member, and lymphoblastoid lines were established by transformation with the Epstein-Barr virus. 17 Genomic DNA was isolated from either cell lines or peripheral lymphocytes. 16, 17 Polymorphic short tandem repeats (also called microsatellites) were amplified by polymerase chain reaction with published nucleotide primer sequences, 18 analyzed on denaturing polyacrylamide gels 16, 17 and visualized by autoradiography.
Linkage Analyses
Two-point logarithm of the odds (LOD) scores were calculated with LINKAGE software (version 5.1; Reference 19). Multipoint LOD scores were calculated with LINKMAP software. 20 The LOD score indicates the statistical likelihood that 2 genetic loci are linked. A LOD score Ն3.0 indicates a significant likelihood of linkage (odds in favor of linkage, 1000:1) to a novel locus. A LOD score Ն1.3 (odds in favor of linkage, 20:1) is sufficient (in Reference 21, see Equation 4.10) to establish significant linkage (PՆ0.05) to a locus identified in other kindreds with a LOD score Ն3.0. A LOD score Յ Ϫ2.0 is generally accepted as evidence against linkage between loci. 16, 17, 19 Penetrance of Carney complex was set at a level of Pϭ0.95 for all analyses, and the disease gene frequency was set at 0.001. Allele frequencies were taken from published data, 18, 22 and all LOD scores reported were confirmed not to be significantly altered by changes in allele frequencies. The HOMOG program was used to test for genetic heterogeneity. 21 
Statistical Analyses
Incidence of specific Carney complex clinical manifestations among adults was defined as the percentage of individuals Ն16 years old with a given finding. To compare frequencies of Carney complex manifestations among all 4 families affected by this syndrome, Kruskall-Wallis nonparametric analysis was performed with CRUNCH software. To further contrast manifestations between pairs of families, a 2-tailed Fisher exact nonparametric test was performed. By use of a Bonferroni correction for multiple comparisons, a limit was established for statistical significance at PϽ0.00083. Carney complex. All affected individuals in these 4 families exhibited cutaneous manifestations of Carney complex, including mucocutaneous hyperpigmentation (ie, lentiginosis, ephelides, and/or blue nevi). Most adults exhibited or had histories of intracardiac myxomas, and some individuals had experienced as many as 3 recurrences despite adequate surgical resection.
Family YA has 16 affected individuals (Table 1) . Eleven affected individuals in family YA were Ն16 years old, and all but 2 had evidence of current or previous intracardiac myxomas. Extracardiac myxomas were noted to occur in the breast and skin. Endocrinologic disorders were noted to involve the adrenal and thyroid glands in affected individuals in family YA. Two individuals had primary pigmented nodular adrenocortical disease with resultant Cushing syndrome requiring adrenalectomy. One individual has been diagnosed with several thoracic and lumbar spine psammomatous melanotic schwannomas.
Clinical features of affected individuals in family YB (Table  1) were similar. Five individuals were affected by Carney complex, and preliminary descriptions of these individuals have previously been described. 23 All were adults, and 4 had been found to have intracardiac tumors. Three individuals had mucocutaneous myxomas, and the remaining 2 individuals had lesions on physical examination that were most consistent with mucocutaneous myxomas, although biopsy was not available. Two individuals also had histories of nonmyxomatous tumors (spleen, thyroid). Other than the individual who had required thyroid resection for malignancy, no other affected individual in family YB had clinical evidence of endocrinologic abnormalities. One individual (II-6) was considered to have an indeterminate diagnosis for initial linkage analyses because complete clinical data were not available.
Six individuals in family YC01 (previously referred to as CAR01 7 ) were affected by Carney complex (Table 1) . Two were affected by intracardiac myxomas, but all had mucocutaneous myxomas. Four individuals had breast myxoid tumors. Nonmyxomatous tumor diagnoses included follicular thyroid carcinoma and pituitary adenoma. All affected individuals in family YC01 had acromegaly and/or primary pigmented nodular adrenocortical disease.
Clinical features of the 8 affected family members in family YC11 (Table 1) have been described previously. 24 In brief, all individuals were known to exhibit typical lentiginosis. Although the eldest affected individual (I-1) was deceased and therefore was not available for further clinical evaluation, all other individuals were affected by mucocutaneous myxomas, but none had cardiac myxomas. Three individuals required surgical intervention for pilonidal sinuses. One individual was affected by a gastric carcinoma, and 2 were diagnosed with breast fibroadenomas. Elevated prolactin levels were detected in 2 women, although no source for this endocrinopathy has yet been identified.
Adults (age Ͼ16 years) in families YA, YB, YC01, and YC11 who were affected by Carney complex shared many similar clinical features. No significant differences were noted in the incidence of cutaneous abnormalities (lentiginosis/hyperpigmentation), the incidence of all myxomas (cardiac and extracardiac), or the incidence of endocrinopathy. However, by KruskallWallis analysis, statistically significant differences were seen in the frequency of cardiac myxomas among the 4 families (Pϭ0.003). By 2-tailed Fisher exact test, the incidence of cardiac myxomas was significantly lower (Pϭ0.007) in family YC11 (0%) than in family YA (82%) or YB (80%). Similarly, Kruskall-Wallis analysis demonstrated statistically significant differences in the frequencies of extracardiac myxomas among the 4 families (Pϭ0.02), with lowest incidence rate in family YA (45%) compared with families YB (100%), YC01 (100%), and YC11 (88%). Finally, the incidence of nonmyxomatous tumors in affected adults among the 4 families differed significantly (Pϭ0.007). Although the 2-tailed Fisher exact test failed to identify significant differences between all pairs of families analyzed, the nonmyxomatous tumor frequency in family YA (9%) was significantly different from the frequency in family YC01 (100%).
Confirmation of Carney Complex Genetic Heterogeneity
We have previously demonstrated that family YA is not linked to the proposed Carney complex locus on chromosome 2p. 16 In this investigation, we now show that family YB is also not linked to the chromosome 2p locus (Table 2) , because LOD scores of greater magnitude than Ϫ2.0 were obtained over the 2p interval. Thus, we are able to confirm genetic heterogeneity of Carney complex. With similar analysis of families YC01 and YC11 (Table 2) , some LOD scores were noted to be between Ϫ1.0 and 1.0, and thus, neither linkage nor nonlinkage to chromosome 2 could be definitively established for these families. Therefore, exploration of other loci to explain Carney complex in families YA, YB, YC01, and YC11 was warranted. 
Demonstration of a Novel Carney Complex Locus on Chromosome 17q
Highly polymorphic short tandem repeat sequences dispersed throughout the genome were analyzed for linkage to the Carney complex disease gene in family YA. Because telomeric rearrangements had been reported 13, 15 to occur on the short arm of chromosome 17 in Carney complex myxomas, our initial efforts focused on this chromosome. No linkage was demonstrated with microsatellites on chromosome 17p (not shown), and analysis with random microsatellites excluded Ͻ1% of the human genome. However, linkage was then detected between microsatellite D17S807 on the long arm of chromosome 17 and the Carney complex in family YA (LOD score, 5.9; ϭ0). Therefore, several additional polymorphic short tandem repeats (D17S944, D17S942, D17S795, and D17S789) on 17q2 were used to analyze family YA further. Linkage was confirmed between the Carney complex in family YA (Table 3 ) and these chromosome 17q polymorphisms; maximal 2-point LOD scores 
ϩ indicates affected; }, diagnosis consistent with history and physical examination but definitive testing not available; and •, not available for evaluation.
achieved demonstrated with odds of Ϸ10 5.9 :1 that the gene responsible for Carney complex is located on chromosome 17q2. Moreover, multipoint analysis of Carney complex in family YA revealed a maximal multipoint LOD score at this locus of 6.16 ( Figure 3 ).
To determine whether the gene responsible for Carney complex in family YA could also be mutated to produce the various clinical features found in affected members of families YB, YC01, and YC11, linkage studies in these families were performed (Table 3) . Two-point LOD scores were calculated between polymorphic loci now established to be linked to Carney complex in family YA and the disease gene in families YB, YC01, and YC11. Linkage was observed between these chromosome 17q loci and the Carney complex disease gene with odds of 10 Genotyping analyses revealed that disease haplotypes of affected individuals are different in each family evaluated. Therefore, families YA, YB, YC01, and YC11 are genetically unrelated, and the Carney complex in these 4 families is not secondary to a common founder effect but rather is the result of independent mutation events.
Data from these haplotype analyses (Table 4) permitted the identification of recombination events to define the Carney complex locus (CAR) genetic interval (Figure 4) . The genotypes of individual II-3 in family YB and of individual II-8 in family YC01 suggested that a recombination event had occurred between locus D17S807 and the Carney complex disease gene. Analyses also identified recombination between the D17S785 locus and the disease gene in individual II-4 (family YB), individual II-7 (family YC01), and individuals II-4 and II-8 (family YC11). Collectively, these data mapped the gene responsible for Carney complex to a 17 cM region between D17S807 and D17S785 that is localized at chromosome 17q2.
Two known tumor suppressor genes map to chromosome 17q: BRCA1 and neurofibromin (NF1). However, their 25 in the RET proto-oncogene in multiple endocrine neoplasia type II. In addition to the chromosome 17q locus reported here, Stratakis and colleagues 7 proposed that a gene defect at chromosome 2p may cause Carney complex. The possibility of still more Carney complex loci still exists, and the relative contributions of mutations at the 17q2 and the 2p loci remain to be determined. Although analyses of previously reported families 7 suggested the existence of the chromosome 2p locus, the limited size of the families available in that study precluded assessment of linkage to chromosome 2p on an individual family basis. Therefore, it is unknown how many of these families actually transmit Carney complex as a result of a chromosome 2p gene defect. It is noteworthy that YC01 was one of the families included in the prior investigation 7 of the putative chromosome 2p locus, but yet it is now shown to be affected by Carney complex on the basis of the chromosome 17q2 gene defect. Moreover, LOD scores for each of the 4 families (YA, YB, YC01, and YC11) reported here demonstrate that in each case, Carney complex is clearly secondary to genetic abnormality at the chromosome 17q2 locus. Thus, we conclude that the CAR locus on chromosome 17q2 is a major genetic cause of familial myxomas and the Carney complex.
Positional cloning studies are currently under way to identify the CAR disease gene. Genes encoding for a wide variety of protein classes may cause Carney complex, and some that have been mapped 3, 22 to chromosome 17q2 include growth hormone, platelet-endothelial cell adhesion molecule I, intercellular adhesion molecule 2, TBX2 transcription factor, and several enzymes for DNA and protein structural modification. Oncogenes and tumor suppressor genes are likely candidates, and several have also been mapped 3, 22 to chromosome 17. Notably, the genetic mapping studies reported here already exclude from the CAR locus, and therefore as candidate Carney complex disease genes, neurofibromin and BRCA1, the chromosome 17q tumor suppressor genes that cause neurofibromatosis and breast cancer, respectively. Refinement of the CAR locus genetic map will facilitate analysis of other candidate genes, and such refinement is feasible given the presence of recombination events in several individuals between the CAR disease gene and the current short tandem repeats (D17S807 and D17S805) flanking the CAR locus.
Investigation of the Carney complex disease gene on chromosome 17q2 will enhance our diagnosis and management of cardiac and extracardiac myxomas. Moreover, in both heritable and acquired cardiac disorders, such as cardiomyopathy and ischemic heart disease, the inability of the terminally differentiated myocyte to proliferate thwarts definitive therapeutics. Cardiac myxomas are thought to arise from rests of subendocardial primitive mesenchymal cells with the capacity to proliferate and to differentiate into multiple cell types. 26 -29 Identification of the Carney complex disease gene will elucidate basic mechanisms that regulate cardiac cell growth and will ultimately suggest modalities to promote cardiac remodeling.
